ArticleFrontiers in oncology2025

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.

Daphne J F Kluitmans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.